Core Insights - Windtree Therapeutics, Inc. has filed a national phase patent application in India for istaroxime, aimed at preventing or reducing the risk of acute myocardial arrhythmia [1][2] - Istaroxime is a first-in-class dual-mechanism therapy designed to enhance both systolic and diastolic cardiac function, showing significant improvements in cardiac function and blood pressure in Phase 2 studies [2][3] Company Overview - Windtree Therapeutics focuses on developing innovative therapies for critical conditions, with a portfolio that includes istaroxime for acute heart failure and cardiogenic shock, as well as preclinical candidates for oncology applications [3] - The company employs a licensing business model and has established partnership out-licenses [3] Product Details - Istaroxime functions as a positive inotropic agent, increasing myocardial contractility and facilitating myocardial relaxation, which is crucial for patients with heart failure [2] - Clinical data indicates that intravenous infusion of istaroxime significantly improves cardiac function without increasing heart rate or the incidence of cardiac rhythm disturbances [2] Strategic Focus - The CEO of Windtree emphasizes the importance of India, with its population exceeding 1.4 billion, in the company's strategic intellectual property plan for istaroxime [2] - The company is preparing for Phase 3 readiness in cardiogenic shock, highlighting its commitment to securing intellectual property protection in key markets [2]
Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India